Gigantism: Clinical diagnosis and description

[en] Gigantism has always been the subject of interest among the general public due to connotations of otherworldly strength and abilities. Until quite recently, the study of gigantism as an illness has not received concerted scientific attention, probably due to its very rare nature. International collaborative research has now led to significant advances in the understanding of the molecular mechanisms responsible for some forms of excessively tall stature. The clinical presentation of pituitary gigantism will be detailed here with emphasis on the specific aspects that are typical to the different genetic causes underlying the disease.

Disciplines :

Endocrinology, metabolism & nutrition

Author, co-author :

NECHIFOR - POTORAC, Iulia ; Centre Hospitalier Universitaire de Liège - CHU > > Service d'endocrinologie clinique

ROSTOMYAN, Liliya ; Centre Hospitalier Universitaire de Liège - CHU > > Service d'endocrinologie clinique

Daly, Adrian ; Centre Hospitalier Universitaire de Liège - CHU > > Service d'endocrinologie clinique

PETROSSIANS, Patrick ; Centre Hospitalier Universitaire de Liège - CHU > > Service d'endocrinologie clinique

BECKERS, Albert ; Centre Hospitalier Universitaire de Liège - CHU > > Service d'endocrinologie clinique

Language :

English

Title :

Gigantism: Clinical diagnosis and description

Publication date :

2021

Main work title :

Gigantism and Acromegaly

Publisher :

Elsevier

Peer reviewed :

Peer reviewed

Available on ORBi :

since 14 June 2022

Statistics

Number of views

154 (6 by ULiège)

Number of downloads

577 (1 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

publications

supporting

mentioning

contrasting

Smart Citations

Citing PublicationsSupportingMentioningContrasting

View Citations

See how this article has been cited at scite.ai

scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

Bibliography

W.W. Herder Acromegaly and gigantism in the medical literature. Case descriptions in the era before and the early years after the initial publication of Pierre Marie (1886) Pituitary 12 3 2009 236-244.
A. Beckers., P. Petrossians., J. Hanson., A.F. Daly The causes and consequences of pituitary gigantism Nat Rev Endocrinol 14 12 2018 705-720.
M. Ozkaya., Z.A. Sayiner., G. Kiran., K. Gul., I. Erkutlu., U. Elboga Ectopic acromegaly due to a growth hormone-secreting neuroendocrine-differentiated tumor developed from ovarian mature cystic teratoma Wien Klin Wochenschr 127 11-12 2015 491-493.
L. Garby., P. Caron., F. Claustrat., P. Chanson., A. Tabarin., V. Rohmer., et al. Clinical characteristics and outcome of acromegaly induced by ectopic secretion of growth hormone-releasing Hormone (GHRH): a French nationwide series of 21 cases J Clin Endocrinol Metab 97 6 2012 2093-2104.
S.A. Leveston., D.W. McKeel., P.J. Buckley., K. Deschryver., M.H. Greider., B.M. Jaffe., et al. Acromegaly and cushing’s syndrome associated with a foregut carcinoid tumor J Clin Endocrinol Metab 53 4 1981 682-689.
L. Rostomyan., A.F. Daly., P. Petrossians., E. Nachev., A.R. Lila., A.L. Lecoq., et al. Clinical and genetic characterization of pituitary gigantism: an international collaborative study in 208 patients Endocr Relat Cancer 22 5 2015 745-757.
D. Iacovazzo., R. Caswell., B. Bunce., S. Jose., B. Yuan., L.C. Hernández-Ramírez., et al. Germline or somatic GPR101 duplication leads to X-linked acrogigantism: a clinico-pathological and genetic study Acta Neuropathol Commun 4 1 2016 56.
L. Rostomyan., A.F. Daly., N. Shah., L. Naves., A. Barlier., M.-L. Jaffrain-Rea., et al. Cardiovascular complications in pituitary gigantism (results of an international study) Endocr Abstr 57 2018 21.
I. Potorac., P. Petrossians., A.F. Daly., F. Schillo., C.B. Slama., S. Nagi., et al. Pituitary MRI characteristics in 297 acromegaly patients based on T2-weighted sequences Endocr Relat Cancer 22 2 2015 169-177.
H.G. Valdes Socin., J. Poncin., J.-F. Vanbellinghen., M.L. Jaffrain-Réa., G. Tamburrano., B. Delemer., et al. Les adénomes hypophysaires familiaux isolés non liés aux syndromes MEN1 et Carney complex: etude multicentrique Ann Endocrinol 62 2001 322.
Beckers A. Familial isolated pituitary adenomas. In: Ninth International Workshop on Multiple Endocrine Neoplasias (MEN2004), Bethesda, MD; 2004.
A.F. Daly., M.L. Jaffrain-Rea., A. Ciccarelli., H. Valdes-Socin., V. Rohmer., G. Tamburrano., et al. Clinical characterization of familial isolated pituitary adenomas J Clin Endocrinol Metab 91 9 2006 3316-3323.
A. Beckers., L.A. Aaltonen., A.F. Daly., A. Karhu Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene Endocr Rev 34 2 2013 239-277.
L.C. Hernández-Ramírez., P. Gabrovska., J. Dénes., K. Stals., G. Trivellin., D. Tilley., et al. Landscape of familial isolated and young-onset pituitary adenomas: prospective diagnosis in AIP mutation carriers J Clin Endocrinol Metab 100 9 2015 E1242-E1254.
O. Vierimaa., M. Georgitsi., R. Lehtonen., P. Vahteristo., A. Kokko., A. Raitila., et al. Pituitary adenoma predisposition caused by germline mutations in the AIP gene Science 312 5777 2006 1228-1230.
A.F. Daly., J.F. Vanbellinghen., K.K. Sok., M.L. Jaffrain-Rea., L.A. Naves., M.A. Guitelman., et al. Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families J Clin Endocrinol Metab 92 5 2007 1891-1896.
A.F. Daly., M.A. Tichomirowa., P. Petrossians., E. Heliövaara., M.L. Jaffrain-Rea., A. Barlier., et al. Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study J Clin Endocrinol Metab 95 11 2010 E373-E383.
R. Mangupli., L. Rostomyan., E. Castermans., J.H. Caberg., P. Camperos., J. Krivoy., et al. Combined treatment with octreotide LAR and pegvisomant in patients with pituitary gigantism: clinical evaluation and genetic screening Pituitary 19 5 2016 507-514.
G. Trivellin., A.F. Daly., F.R. Faucz., B. Yuan., L. Rostomyan., D.O. Larco., et al. Gigantism and acromegaly due to Xq26 microduplications and GPR101 mutation N Engl J Med 371 25 2014 2363-2374.
A. Beckers., M.B. Lodish., G. Trivellin., L. Rostomyan., M. Lee., F.R. Faucz., et al. X-linked acrogigantism syndrome: clinical profile and therapeutic responses Endocr Relat Cancer 22 3 2015 353-367.
L.A. Naves., A.F. Daly., L.A. Dias., B. Yuan., J.C.O. Zakir., G.B. Barra., et al. Aggressive tumor growth and clinical evolution in a patient with X-linked acro-gigantism syndrome Endocrine 51 2 2016 236-244.
D. Abboud., A.F. Daly., N. Dupuis., M.A. Bahri., A. Inoue., A. Chevigné., et al. GPR101 drives growth hormone hypersecretion and gigantism in mice via constitutive activation of Gs and Gq/11 Nat Commun 11 1 2020 4752.
A.F. Daly., B. Yuan., F. Fina., J.H. Caberg., G. Trivellin., L. Rostomyan., et al. Somatic mosaicism underlies X-linked acrogigantism syndrome in sporadic male subjects Endocr Relat Cancer 23 4 2016 221-233.
R.V. Thakker., P.J. Newey., G.V. Walls., J. Bilezikian., H. Dralle., P.R. Ebeling., et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1) J Clin Endocrinol Metab 97 9 2012 2990-3011.
L. Vroonen., M.L. Jaffrain-Rea., P. Petrossians., G. Tamagno., P. Chanson., L. Vilar., et al. Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients Eur J Endocrinol 167 5 2012 651-662.
M. Benito., S.L. Asa., V.A. LiVolsi., V.A. West., P.J. Snyder Gonadotroph tumor associated with multiple endocrine neoplasia type 1 J Clin Endocrinol Metab 90 1 2005 570-574.
B.W. Scheithauer., K. Kovacs., V. Nose., M. Lombardero., Y.R. Osamura., R.V. Lloyd., et al. Multiple endocrine neoplasia type 1-associated thyrotropin-producing pituitary carcinoma: report of a probable de novo example Hum Pathol 40 2 2009 270-278.
B. Vergès., F. Boureille., P. Goudet., A. Murat., A. Beckers., G. Sassolas., et al. Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study J Clin Endocrinol Metab 87 2 2002 457-465.
C.A. Stratakis., D.H. Schussheim., S.M. Freedman., M.F. Keil., S.D. Pack., S.K. Agarwal., et al. Pituitary macroadenoma in a 5-year-old: an early expression of multiple endocrine neoplasia type 1 1 J Clin Endocrinol Metab 85 12 2000 4776-4780.
S.E. Carty., A.K. Helm., J.A. Amico., M.R. Clarke., T.P. Foley., C.G. Watson., et al. The variable penetrance and spectrum of manifestations of multiple endocrine neoplasia type 1 Surgery 124 6 1998 1106-1113.
Y. Wu., L. Gao., X. Guo., Z. Wang., W. Lian., K. Deng., et al. Pituitary adenomas in patients with multiple endocrine neoplasia type 1: a single-center experience in China Pituitary 22 2 2019 113-123.
N.S. Pellegata., L. Quintanilla-Martinez., H. Siggelkow., E. Samson., K. Bink., H. Höfler., et al. Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans Proc Natl Acad Sci U S A 103 42 2006 15558-15563.
M. Lee., N.S. Pellegata Multiple endocrine neoplasia type 4 Front Horm Res 41 2013 63-78.
M.H. Schernthaner-Reiter., G. Trivellin., C.A. Stratakis MEN1, MEN4, and Carney complex: pathology and molecular genetics Neuroendocrinology 103 1 2016 18-31.
S. Sambugaro., M. Di Ruvo., M.R. Ambrosio., N.S. Pellegata., M. Bellio., A. Guerra., et al. Early onset acromegaly associated with a novel deletion in CDKN1B 5′UTR region Endocrine 49 1 2015 58-64.
M.A. Tichomirowa., M. Lee., A. Barlier., A.F. Daly., I. Marinoni., M.L. Jaffrain-Rea., et al. Cyclin-dependent kinase inhibitor 1B(CDKN1B) gene variants in AIP mutation-negative familial isolated pituitary adenoma kindreds Endocr Relat Cancer 19 3 2012 233-241.
L.B. Nachtigall., F.J. Guarda., K.E. Lines., A. Ghajar., L. Dichtel., G. Mumbach., et al. Clinical MEN-1 among a large cohort of patients with acromegaly J Clin Endocrinol Metab 105 6 2020 e2271-e2281.
J. Aidan Carney., H. Gordon., P.C. Carpenter., B. Vittal Shenoy., V.L.W. Go The complex of myxomas, spotty pigmentation, and endocrine overactivity Medicine (Baltimore) 64 4 1985 270-283.
C.A. Stratakis., L.S. Kirschner., J.A. Carney Clinical and molecular features of the Carney complex: diagnostic criteria and recommendations for patient evaluation J Clin Endocrinol Metab 86 9 2001 4041-4046.
R. Correa., P. Salpea., C.A. Stratakis Carney complex: an update Eur J Endocrinol 173 4 2015 M85-M97.
S.D. Pack., L.S. Kirschner., E. Pak., Z. Zhuang., J.A. Carney., C.A. Stratakis Genetic and histologic studies of somatomammotropic pituitary tumors in patients with the ‘complex of spotty skin pigmentation, myxomas, endocrine overactivity and schwannomas’ (Carney complex) J Clin Endocrinol Metab 85 10 2000 3860-3865.
T. Cuny., T.T. Mac., P. Romanet., H. Dufour., I. Morange., F. Albarel., et al. Acromegaly in Carney complex Pituitary 22 5 2019 456-466.
C.E. Dumitrescu., M.T. Collins McCune-Albright syndrome Orphanet J Rare Dis 3 2008 12.
S. Salenave., A.M. Boyce., M.T. Collins., P. Chanson Acromegaly and McCune-Albright syndrome J Clin Endocrinol Metab 99 6 2014 1955-1969.
A.O. Vortmeyer., S. Gläsker., G.U. Mehta., M.S. Abu-Asab., J.H. Smith., Z. Zhuang., et al. Somatic GNAS mutation causes widespread and diffuse pituitary disease in acromegalic patients with McCune-Albright syndrome J Clin Endocrinol Metab 97 7 2012 2404-2413.
M.K. Javaid., A. Boyce., N. Appelman-Dijkstra., J. Ong., P. Defabianis., A. Offiah., et al. Best practice management guidelines for fibrous dysplasia/McCune-Albright syndrome: a consensus statement from the FD/MAS international consortium Orphanet J Rare Dis 14 1 2019 139.
V. Vasilev., A.F. Daly., A. Thiry., P. Petrossians., F. Fina., L. Rostomyan., et al. McCune-Albright syndrome: a detailed pathological and genetic analysis of disease effects in an adult patient J Clin Endocrinol Metab 99 10 2014 E2029-E2038.
P. Xekouki., A. Brennand., B. Whitelaw., K. Pacak., C.A. Stratakis The 3PAs: an update on the association of pheochromocytomas, paragangliomas, and pituitary tumors Horm Metab Res 51 7 2019 419-436.
J. Dénes., F. Swords., E. Rattenberry., K. Stals., M. Owens., T. Cranston., et al. Heterogeneous genetic background of the association of pheochromocytoma/paraganglioma and pituitary adenoma: Results from a large patient cohort J Clin Endocrinol Metab 100 3 2015 E531-E541.
A.F. Daly., E. Castermans., L. Oudijk., M.A. Guitelman., P. Beckers., I. Potorac., et al. Pheochromocytomas and pituitary adenomas in three patients with MAX exon deletions Endocr Relat Cancer 25 5 2018 L37-L42.
P. Xekouki., K. Pacak., M. Almeida., C.A. Wassif., P. Rustin., M. Nesterova., et al. Succinate dehydrogenase (SDH) D subunit (SDHD) inactivation in a growth-hormone-producing pituitary tumor: a new association for SDH? J Clin Endocrinol Metab 97 3 2012 E357-E366.

Similar publications

Sorry the service is unavailable at the moment. Please try again later.